Latest Insider Transactions at Laboratory Corp Of America Holdings (LH)
This section provides a real-time view of insider transactions for Laboratory Corp Of America Holdings (LH). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of LABORATORY CORP OF AMERICA HOLDINGS to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of LABORATORY CORP OF AMERICA HOLDINGS's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 02
2024
|
Amy B. Summy EVP, Chief Marketing Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
80
-2.06%
|
$17,680
$221.54 P/Share
|
|
Feb 02
2024
|
Amy B. Summy EVP, Chief Marketing Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
246
+5.96%
|
-
|
|
Feb 02
2024
|
Brian J Caveney EVP, Pres of ED, CMO & CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
166
-0.8%
|
$36,686
$221.54 P/Share
|
|
Feb 02
2024
|
Brian J Caveney EVP, Pres of ED, CMO & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
495
+2.33%
|
-
|
|
Feb 02
2024
|
Lance Berberian EVP, CIO & CTO |
SELL
Payment of exercise price or tax liability
|
Direct |
89
-0.38%
|
$19,669
$221.54 P/Share
|
|
Feb 02
2024
|
Lance Berberian EVP, CIO & CTO |
BUY
Exercise of conversion of derivative security
|
Direct |
331
+1.41%
|
-
|
|
Feb 02
2024
|
Glenn A Eisenberg Chief Financial Officer, EVP |
SELL
Payment of exercise price or tax liability
|
Direct |
228
-0.53%
|
$50,388
$221.54 P/Share
|
|
Feb 02
2024
|
Glenn A Eisenberg Chief Financial Officer, EVP |
BUY
Exercise of conversion of derivative security
|
Direct |
856
+1.95%
|
-
|
|
Feb 02
2024
|
Jonathan P. Di Vincenzo EVP, Pres, Central Labs & Intl |
SELL
Payment of exercise price or tax liability
|
Direct |
85
-2.36%
|
$18,785
$221.54 P/Share
|
|
Feb 02
2024
|
Jonathan P. Di Vincenzo EVP, Pres, Central Labs & Intl |
BUY
Exercise of conversion of derivative security
|
Direct |
246
+6.4%
|
-
|
|
Feb 02
2024
|
Adam H Schechter President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
822
-1.64%
|
$181,662
$221.54 P/Share
|
|
Feb 02
2024
|
Adam H Schechter President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
3,094
+5.83%
|
-
|
|
Feb 02
2024
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
132
-1.82%
|
$29,172
$221.54 P/Share
|
|
Feb 02
2024
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
BUY
Exercise of conversion of derivative security
|
Direct |
495
+6.39%
|
-
|
|
Feb 02
2024
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
71
-0.9%
|
$15,691
$221.54 P/Share
|
|
Feb 02
2024
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
264
+3.23%
|
-
|
|
Dec 15
2023
|
Jonathan P. Di Vincenzo EVP, Pres, Central Labs & Intl |
SELL
Payment of exercise price or tax liability
|
Direct |
19
-0.56%
|
$4,161
$219.5 P/Share
|
|
Dec 15
2023
|
Jonathan P. Di Vincenzo EVP, Pres, Central Labs & Intl |
BUY
Exercise of conversion of derivative security
|
Direct |
64
+1.86%
|
-
|
|
Nov 16
2023
|
Peter J Wilkinson SVP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
1,384
-39.87%
|
$290,640
$210.71 P/Share
|
|
Oct 12
2023
|
Kirsten Marie Kliphouse Director |
BUY
Exercise of conversion of derivative security
|
Direct |
372
+50.0%
|
-
|
|
Aug 08
2023
|
Kerrii B Anderson Director |
SELL
Open market or private sale
|
Direct |
5,000
-24.66%
|
$1,055,000
$211.57 P/Share
|
|
Aug 01
2023
|
Peter J Wilkinson SVP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
17
-0.49%
|
$3,621
$213.61 P/Share
|
|
Aug 01
2023
|
Peter J Wilkinson SVP, Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
56
+1.58%
|
-
|
|
Jun 29
2023
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
212
-2.71%
|
$50,880
$240.0 P/Share
|
|
May 19
2023
|
Paul R Kirchgraber CEO, Covance Drug Development |
SELL
Open market or private sale
|
Direct |
4,300
-24.93%
|
$928,800
$216.91 P/Share
|
|
May 19
2023
|
Paul R Kirchgraber CEO, Covance Drug Development |
BUY
Exercise of conversion of derivative security
|
Direct |
4,300
+19.96%
|
$782,600
$182.51 P/Share
|
|
May 18
2023
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
SELL
Open market or private sale
|
Direct |
1,500
-18.32%
|
$324,000
$216.77 P/Share
|
|
May 18
2023
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+15.48%
|
$195,000
$130.6 P/Share
|
|
Mar 31
2023
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
SELL
Open market or private sale
|
Direct |
3,897
-36.82%
|
$876,825
$225.81 P/Share
|
|
Mar 30
2023
|
Adam H Schechter President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
18,646
-28.45%
|
$4,176,704
$224.7 P/Share
|
|
Mar 30
2023
|
Adam H Schechter President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
42,353
+39.26%
|
-
|
|
Mar 30
2023
|
Glenn A Eisenberg Chief Financial Officer, EVP |
SELL
Payment of exercise price or tax liability
|
Direct |
5,179
-10.94%
|
$1,160,096
$224.7 P/Share
|
|
Mar 30
2023
|
Glenn A Eisenberg Chief Financial Officer, EVP |
BUY
Grant, award, or other acquisition
|
Direct |
11,715
+19.83%
|
-
|
|
Mar 30
2023
|
Paul R Kirchgraber CEO, Covance Drug Development |
SELL
Payment of exercise price or tax liability
|
Direct |
2,886
-18.23%
|
$646,464
$224.7 P/Share
|
|
Mar 30
2023
|
Paul R Kirchgraber CEO, Covance Drug Development |
BUY
Grant, award, or other acquisition
|
Direct |
6,763
+29.93%
|
-
|
|
Mar 30
2023
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,866
-21.31%
|
$641,984
$224.7 P/Share
|
|
Mar 30
2023
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
BUY
Grant, award, or other acquisition
|
Direct |
6,763
+33.46%
|
-
|
|
Mar 30
2023
|
Lance Berberian EVP, CIO & CTO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,799
-7.29%
|
$402,976
$224.7 P/Share
|
|
Mar 30
2023
|
Lance Berberian EVP, CIO & CTO |
BUY
Grant, award, or other acquisition
|
Direct |
4,509
+15.45%
|
-
|
|
Mar 30
2023
|
Brian J Caveney EVP, Pres of ED, CMO & CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,990
-12.9%
|
$669,760
$224.7 P/Share
|
|
Mar 30
2023
|
Brian J Caveney EVP, Pres of ED, CMO & CSO |
BUY
Grant, award, or other acquisition
|
Direct |
6,763
+22.59%
|
-
|
|
Mar 30
2023
|
Judith C Seltz EVP, CHRO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,164
-21.78%
|
$260,736
$224.7 P/Share
|
|
Mar 30
2023
|
Judith C Seltz EVP, CHRO |
BUY
Grant, award, or other acquisition
|
Direct |
3,381
+38.75%
|
-
|
|
Mar 30
2023
|
Amy B. Summy EVP, Chief Marketing Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,269
-25.88%
|
$284,256
$224.7 P/Share
|
|
Mar 30
2023
|
Amy B. Summy EVP, Chief Marketing Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,234
+39.74%
|
-
|
|
Mar 30
2023
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,371
-14.97%
|
$307,104
$224.7 P/Share
|
|
Mar 30
2023
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,609
+28.26%
|
-
|
|
Mar 30
2023
|
Peter J Wilkinson SVP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
526
-13.29%
|
$117,824
$224.7 P/Share
|
|
Mar 30
2023
|
Peter J Wilkinson SVP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,798
+31.24%
|
-
|
|
Mar 02
2023
|
Amy B. Summy EVP, Chief Marketing Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
374
-18.31%
|
$89,386
$239.46 P/Share
|